Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer
Completed · Phase 2
Conditions studied: Head and Neck Cancer
In brief
RATIONALE: Combretastatin A4 phosphate may stop the growth of anaplastic thyroid cancer by stopping blood flow to the tumor. PURPOSE: This phase II trial is studying how well combretastatin A4 phosphate works in treating patients with advanced recurrent or metastatic anaplastic thyroid cancer.
Key facts
- Study ID
- NCT00060242
- Run by
- Case Comprehensive Cancer Center
- People needed
- 26
- Starts
- 2003-02-01
- Expected to finish
- 2008-01-01
- Last updated by the study team
- 2010-06-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Josephine Ford Cancer Center at Henry Ford Hospital — Detroit, Michigan, United States
- Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center — Cleveland, Ohio, United States
- Hillman Cancer Center at University of Pittsburgh Cancer Institute — Pittsburgh, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.